BiotechTube

Pembrolizumab

Phase 2Active
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous T Cell Lymphoma

Conditions

Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome

Trial Timeline

Jan 15, 2019 → Sep 1, 2025

NCT ID
NCT03385226

About Pembrolizumab

Pembrolizumab is a phase 2 stage product being developed by Merck for Cutaneous T Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03385226. Target conditions include Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome.

What happened to similar drugs?

7 of 20 similar drugs in Cutaneous T Cell Lymphoma were approved

Approved (7) Terminated (1) Active (12)
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
✅ONTAKEisaiApproved
✅MogamulizumabKyowa KirinApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Normal Saline (Placebo)NovartisApproved
✅BexaroteneBausch HealthApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT02083484Pre-clinicalCompleted
NCT07302347Phase 1/2Recruiting
NCT07089992Phase 2Recruiting
NCT07007273Phase 2Recruiting
NCT04569461Phase 2Withdrawn
NCT05815927Phase 3Recruiting
NCT05852223Phase 2Recruiting
NCT05879120Phase 2Withdrawn
NCT06004336Phase 2Recruiting
NCT05496036Phase 2Recruiting
NCT05131919Phase 2Active
NCT05197322Phase 2Recruiting
NCT05406713Phase 2Active
NCT05025813Phase 2Recruiting
NCT06413095Phase 1Completed
NCT05191472Phase 2Terminated
NCT05204160Phase 2Withdrawn
NCT04575961Phase 2Active
NCT04417166Phase 2Recruiting
NCT05188508Phase 2Recruiting

Competing Products

20 competing products in Cutaneous T Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
43
ONTAKEisaiApproved
43
E7777 9 mcg/kgEisaiPhase 3
40
ONTAKEisaiApproved
43
MogamulizumabKyowa KirinApproved
47
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
36
MogamulizumabKyowa KirinPhase 2
39
KW-0761 + VorinostatKyowa KirinPhase 3
40
EnzastaurinEli LillyPhase 2
35
Clopidogrel + TicagrelorAstraZenecaApproved
43
PembrolizumabMerckPhase 2
42
Comparator: vorinostatMerckPre-clinical
26
TR701 FAMerckPhase 2
35
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
35
PembrolizumabMerckPhase 2
42
Tulisokibart + PlaceboMerckPhase 2
39
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
35
Pembrolizumab + MogamulizumabMerckPhase 2
42
TR-701 FA + LinezolidMerckPhase 3
40
Pimasertib + DacarbazineMerckPhase 2
35